Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy

Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy

Background: Systemic Lutetium-177 prostate-specific membrane antigen-617 radioligand therapy (Lu-177-PSMA-617-RLT) is a novel treatment approach in patients suffering from metastasized castration-resistant prostate cancer. Nonetheless, a therapeutic response may fail to appear in a proportion of pat...

Full description

Bibliographic Details
Main Authors:	Caliebe, A. (Author), Jüptner, M. (Author), Lützen, U. (Author), Marx, M. (Author), Osmonov, D. (Author), Wrenger, R. (Author), Zhao, Y. (Author), Zuhayra, M. (Author)
Format:	Article
Language:	English
Published:	BioMed Central Ltd 2022
Subjects:	Lu-177-PSMA-617 Radioligand therapy, castration-resistant prostate cancer Survival analysis
Online Access:	View Fulltext in Publisher

Similar Items

Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy
by: Florian Rosar, et al.
Published: (2021-05-01)

Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
by: Daniel Groener, et al.
Published: (2021-07-01)

Renal Safety of [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function
by: Florian Rosar, et al.
Published: (2021-06-01)

Assessment of salivary gland function after 177Lu-PSMA radioligand therapy: Current concepts in imaging and management
by: Friedman, K.P, et al.
Published: (2022)

Correlation of An Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after <sup>177</sup>Lu-PSMA-617 Radioligand Therapy
by: Friederike Völter, et al.
Published: (2021-03-01)

Salvage Radioligand Therapy with Repeated Cycles of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Marrow Involvement
by: Daniel Groener, et al.
Published: (2021-08-01)

Outcome of <sup>177</sup>Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer
by: Nicolai Mader, et al.
Published: (2021-08-01)

177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians
by: Ai, S., et al.
Published: (2022)

Efficacy and Safety of [<sup>225</sup>Ac]Ac-PSMA-617 Augmented [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis
by: Florian Rosar, et al.
Published: (2021-05-01)

In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2nd Cycle Is Better Predictor of Overall Survival of Prostate Cancer Patients Treated With 177Lu-PSMA
by: Vikas Prasad, et al.
Published: (2021-03-01)

Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
by: Andreas Rinscheid, et al.
Published: (2020-06-01)

PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under <sup>177</sup>Lu-PSMA-617 Radioligand Therapy
by: Liam Widjaja, et al.
Published: (2021-06-01)

<sup>177</sup>Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
by: Yasemin Sanli, et al.
Published: (2021-04-01)

Response Assessment and Prediction of Progression-Free Survival by <sup>68</sup>Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing <sup>177</sup>Lu-PSMA-617 Radioligand Therapy
by: Fadi Khreish, et al.
Published: (2021-07-01)

Response and Toxicity to the Second Course of 3 Cycles of <sup>177</sup>Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer
by: Sazan Rasul, et al.
Published: (2021-05-01)

Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T
by: Julia Brosch-Lenz, et al.
Published: (2021-03-01)

Value of Combined PET Imaging with [<sup>18</sup>F]FDG and [<sup>68</sup>Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [<sup>177</sup>Lu]Lu-PSMA-617 RLT
by: Fadi Khreish, et al.
Published: (2021-08-01)

LU-177-PSMA TREATMENT FOR METASTATIC PROSTATE CANCER – CASE EXAMPLES OF MIRACLE RESPONSES
by: K. Kairemo, et al.
Published: (2018-03-01)

External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies
by: J. Kurth, et al.
Published: (2018-04-01)

Development of Discordant Hypermetabolic Prostate Cancer Lesions in the Course of [<sup>177</sup>Lu]PSMA Radioligand Therapy and Their Possible Influence on Patient Outcome
by: Philipp E. Hartrampf, et al.
Published: (2021-08-01)

68Ga, 44Sc and 177Lu-labeled AAZTA5-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues
by: Jean-Philippe Sinnes, et al.
Published: (2020-11-01)

USE OF <sup>177</sup>Lu-PSMA FOR RADIONUCLIDE THERAPY IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER
by: A. A. Medvedeva, et al.
Published: (2021-06-01)

Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
by: Zool Hilmi Awang, et al.
Published: (2018-05-01)

<sup>177</sup>Lu-PSMA-617 Therapy in Mice, with or without the Antioxidant α<sub>1</sub>-Microglobulin (A1M), Including Kidney Damage Assessment Using <sup>99m</sup>Tc-MAG3 Imaging
by: Amanda Kristiansson, et al.
Published: (2021-02-01)

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial
by: Bastiaan M. Privé, et al.
Published: (2020-09-01)

Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management
by: Katharina Kessel, et al.
Published: (2021-07-01)

Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years
by: Majid Assadi, et al.
Published: (2020-01-01)

Radionuclide generator-based production of therapeutic 177Lu from its long-lived isomer 177mLu
by: Rupali Bhardwaj, et al.
Published: (2019-07-01)

PSMA Theranostics: Science and Practice
by: Kgomotso Mokoala, et al.
Published: (2021-08-01)

An exceptional response to 177LuPSMA undermined by neuroendocrine transformation
by: Pretoria Bilinski, et al.
Published: (2021-01-01)

Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients
by: Murali Kesavan, et al.
Published: (2021-03-01)

PSMA-D4 Radioligand for Targeted Therapy of Prostate Cancer: Synthesis, Characteristics and Preliminary Assessment of Biological Properties
by: Piotr Garnuszek, et al.
Published: (2021-03-01)

Albumin-Binding PSMA Radioligands: Impact of Minimal Structural Changes on the Tissue Distribution Profile
by: Luisa M. Deberle, et al.
Published: (2020-05-01)

Understanding the mechanism of 177Lu- PSMA617 radioligand therapy and evaluating its potential role in the treatment of metastatic castrate resistant prostate cancer (mCRPC)
by: Joshi, Jay
Published: (2020)

Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors?
by: Veronika Barbara Felber, et al.
Published: (2021-02-01)

Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer
by: Christoph Henkenberens, et al.
Published: (2021-04-01)

Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives
by: Konstantin Egon Seitzer, et al.
Published: (2021-07-01)

Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A''-DTPA-DUPA-Pep
by: Benjamin Baur, et al.
Published: (2014-04-01)

Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
by: Madhav Prasad Yadav, et al.
Published: (2019-02-01)

Tissue dose estimation after extravasation of 177Lu-DOTATATE
by: Perrine Tylski, et al.
Published: (2021-03-01)